Form 4 for CORT CORCEPT THERAPEUTICS INC
Accepted 2026-05-05 16:30:11 ET · period of report 2026-05-01 · accession 0001193125-26-206540 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TI | 2026-05-05 16:30 | 2026-05-01 | CORT | BELANOFF JOSEPH K | CEO, Dir | S - Sale | $50.10 | -40.0K | 2.88M | -1% | -$2.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-01 | S | D | 40,000 | $50.10 | 2,878,326 | I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 | — | — | (F1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. (F2) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.35 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. (F3) Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. |